| Home | E-Submission | Sitemap | Contact Us |  
The Korean Journal of Medicine 2009;76(1): 12-17.
류마티스 관절염의 새로 개발된 치료제
New drugs for Rheumatoid arthritis
Young-Il Seo
Since the late 1990s, based on scientific advancement and biotechnological improvement, many effective drugs such as leflunomide and biologic agents for rheumatoid arthritis (RA) have been developed. These include TNF-α inhibitors such as etanercept, infliximab, and adalimumab, a peripheral B-cell depleting agent such as rituximab, CTLA-4 Ig such as abatacept, and IL-1 receptor antagonist such as anakira. These new agents have provided good efficacy in the treatment of patents with severe or refractory rheumatoid arthritis and have provided retardation or prevention of radiographic progression or joint destruction despite some side effects such as tuberculosis, infection, malignancies. In this review, new therapeutic alternatives would be given, and chances for more improved outcomes in the care of patients with rheumatoid arthritis provided. (Korean J Med 76:12-17, 2009)
Keywords: Biologic agent; TNF-α inhibitor; anti-B cell therapy; CTLA4; rheumatoid arthritis
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
A New Medical Therapy for Axial Spondyloarthritis  2018 October;93(5)
New Drugs for Obesity Treatment  2016 February;90(2)
Ultrasonographic Findings in Rheumatoid Arthritis  2015 December;89(6)
Non-Infective Endocarditis in a Patient with Rheumatoid Arthritis  2015 January;88(1)
New Classification Criteria for Rheumatoid Arthritis  2014 October;87(4)
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community